The collaboration of CD39 (in macrophages but not HCC cells) with CD73 (mostly in HCC cells but not macrophages) fulfills the sequential activation of the ATP–adenosine pathway, impairs CD8+ T cell function, and finally builds a PD1 antibody-resistant tumor environment. The gene discussed is ENTPD1; the disease is hepatocellular carcinoma.